From the Food and Drug Administration.
Nightingale
S L
SL
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects*; D001944:Breath Tests; D000077404:Cidofovir; D003596:Cytosine / Q000009:adverse effects / Q000031:analogs & derivatives*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000175:diagnosis*; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects*; D019736:Prostheses and Implants; D051437:Renal Insufficiency / Q000139:chemically induced*; D013123:Spinal Fusion / Q000295:instrumentation*; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir